Call for Abstract

32nd International Conference on Vaccines and Immunization
R&D, B2B, will be organized around the theme “Prospects and Development of Prophylactic & Therapeutic Vaccines”

Vaccines 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vaccines 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Cholera, Shigella, Meningitis, Dengue, Rotavirus
  • Track 1-2Single-dose tetanus toxoid (TT), Thermos table poliomyelitis, Acellular pertussis, Tuberculosis
  • Track 1-3Chickenpox
  • Track 1-4Hepatitis A
  • Track 1-5Yello fever
  • Track 2-1Rotavirus & Smallpox Vaccines
  • Track 2-2Influenza vaccines
  • Track 2-3Bordetella Vaccine
  • Track 2-4OPV Vaccine
  • Track 2-5Rubella Vaccine
  • Track 3-1HPV vaccine
  • Track 3-2Hepatitis B vaccine
  • Track 3-3Cancer treatment vaccines
  • Track 4-1DTaP: Diphtheria, tetanus, and acellular pertussis vaccine
  • Track 4-2Hib: Haemophilus influenzae type b vaccine.
  • Track 4-3RV: Rotavirus vaccine.
  • Track 4-4Polio
  • Track 4-5Toxoid vaccines
  • Track 4-6Conjugate vaccines
  • Track 5-1DNA vaccines
  • Track 5-2Vaccines against viral toxins
  • Track 5-3Inactivated vaccines
  • Track 5-4Live attenuated vaccines
  • Track 5-5Peptide vaccines
  • Track 6-1Hepatitis A vaccination
  • Track 6-2Hepatitis B vaccination
  • Track 6-3Meningococcal vaccination
  • Track 7-1Risk factor
  • Track 7-2Lifestyle
  • Track 7-3Genetics
  • Track 7-4Medical conditions
  • Track 8-1Chickenpox
  • Track 8-2Diphtheria
  • Track 8-3whooping cough
  • Track 8-4Hepatitis A
  • Track 8-5Hepatitis B.
  • Track 8-6Influenza
  • Track 8-7Measles, mumps, rubella (MMR) •
  • Track 10-1Inactivated whole virus vaccines
  • Track 10-2Recombinant viral proteins
  • Track 10-3Synthetic Peptides
  • Track 10-4DNA vaccines
  • Track 12-1Indonesia - vaccinations for rabies, Japanese encephalitis and cholera
  • Track 12-2Thailand - vaccinations for Hepatitis A and B as well as typhoid and influenza
  • Track 12-3India -rabies and Japanese encephalitis.
  • Track 12-4China - rabies, Japanese and tick-borne encephalitis and cholera
  • Track 12-5Vietnam -Hepatitis A and B, typhoid and influenza
  • Track 13-1Recent focus in Virology
  • Track 13-2Vectors / adjuvants / drug delivery
  • Track 13-3Vaccines discovery & formulation
  • Track 13-4Vaccines Bioprocessing & Manufacturing
  • Track 13-5Business Development & investment in New Approaches
  • Track 14-1Canine Leptospira Vaccines
  • Track 14-2Canine Rabies Virus Vaccines
  • Track 14-3Canine Non-Core Vaccines
  • Track 14-4Canine Influenza Virus (CIV)
  • Track 14-5Canine Core Vaccines
  • Track 15-1Viral Hepatitis, Influenza Vaccine
  • Track 15-2Cholera
  • Track 15-3Tetanus
  • Track 15-4Diphtheria
  • Track 15-5Tuberculosis (TB)
  • Track 15-6Research on cancer vaccines
  • Track 15-7Tetanus, diphtheria, acellular pertussis vaccine
  • Track 15-8Vaccines against vector borne Diseases
  • Track 15-9Virus-like particles as vaccines, vectors and adjutants
  • Track 15-10Typhoid
  • Track 17-1Cancer immunoprevention
  • Track 17-2Therapeutic cancer vaccines
  • Track 17-3Preventive cancer vaccines
  • Track 17-4Oncoviruses & oncobacteria
  • Track 17-5Malaria Vaccines for Pregnants and Newborns
  • Track 17-6Novel Methods in TB vaccination
  • Track 17-7Tumour antigen
  • Track 18-1Mechanistic basis for DNA-raised immune responses
  • Track 18-2Plasmid Vector
  • Track 18-3Recombinant protein vaccines
  • Track 18-4Modulation of immune response
  • Track 18-5DNA vaccines delivery
  • Track 19-1HPV infection
  • Track 19-2Neutralising antibodies and CTL activation
  • Track 19-3Strong immune response
  • Track 19-4Viral progression 1 to 6 months from infection to disease
  • Track 19-5Systemic infection
  • Track 19-6HBV infection
  • Track 19-7Natural immunity does not reliably prevent from infection
  • Track 19-8 Innate immune response, late induction of adaptive response (low antibody levels after long exposure to infection)
  • Track 19-9Virus elimination via natural cell clearance
  • Track 19-10Viral entry occurs rapidly, but infected cell shows no inflammation
  • Track 19-11Many viral subtypes
  • Track 19-12 Attenuation of immune mechanism
  • Track 19-13Local infection at the mucosa
  • Track 19-14Immune mechanisms in subjects who recovered from HBV infection provide lifelong immunity
  • Track 20-1Therapeutic Abs come from critical screenings of in vivo and in vitromethods
  • Track 20-2Bispecific Abs increase specificity and broaden the range of therapeutic MOA.
  • Track 20-3Optimized Ab leads undergo HFA, affinity maturation, and developability assessment.
  • Track 20-4Fc optimization is critical for antibody pharmacokinetics and pharmacodynamics
  • Track 21-1Signs and Symptoms: Fever and extreme coldness,Cough etc
  • Track 21-2Types of virus:Influenzavirus A ,Influenzavirus B ,Influenzavirus C
  • Track 22-1Next-Generation Adjuvants
  • Track 22-2Advances in DNA Vaccines, TLRS and Combination Adjuvants
  • Track 22-3Addressing Unmet Vaccine Needs
  • Track 22-4DNA delivery technologies
  • Track 22-5Needle-free vaccine delivery
  • Track 22-6Nanopatch Technologies
  • Track 23-1Creation of the vaccine concept
  • Track 23-2Evaluation of vaccine efficacy in test tubes and animals
  • Track 23-3Current Focus in Virology Research
  • Track 23-4Regulatory and Economical Aspects in Virology
  • Track 23-5Current Challenges in Vaccine R & D
  • Track 24-1DNA vaccines
  • Track 24-2Recombinant (protein subunit) vaccines
  • Track 25-1Identification (discovery) of relevant antigens (e.g. screening)
  • Track 25-2Creation of the vaccine concept
  • Track 25-3Current Focus in Virology Research
  • Track 25-4Regulatory and Economical Aspects in Virology
  • Track 26-1Asplenia
  • Track 26-2Varicella (Chickenpox)
  • Track 26-3MMR (Measles, Mumps, & Rubella)
  • Track 26-4Hepatitis B
  • Track 26-5Weakened Immune System
  • Track 26-6Lung Disease including Asthma
  • Track 26-7Liver Disease
  • Track 26-8HIV Infection
  • Track 26-9Heart Disease, Stroke, or Other Cardiovascular Disease
  • Track 26-10Diabetes Type 1 and Type 2
  • Track 26-11Meningococcal
  • Track 27-1What is adenovirus
  • Track 27-2pneumonia
  • Track 27-3blood in the urine or stool
  • Track 27-4Serious Problems
  • Track 27-5fever (about 1 person in 100)
  • Track 27-6diarrhea (about 1 person in 10)
  • Track 27-7abdominal pain, cough, nausea (about 1 person in 7)
  • Track 27-8stuffy nose, sore throat, joint pain (about 1 person in 6)
  • Track 27-9 headaches, upper respiratory tract infection (about 1 person in 3)
  • Track 27-10Mild Problems
  • Track 27-11What are the risks from adenovirus vaccine
  • Track 27-12 Precautions
  • Track 27-13Adenovirus vaccine
  • Track 27-14inflammation of the stomach or intestines
  • Track 28-1Anthrax vaccines
  • Track 28-2Poliomyelitis vaccines
  • Track 28-3Tick-borne encephalitis vaccines
  • Track 28-4Haemophilus influenza type b vaccines
  • Track 28-5Rabies vaccines
  • Track 28-6Varicella and herpes zoster (shingles) vaccines
  • Track 28-7Human papilloma-virus vaccines
  • Track 28-8Rotavirus gastroenteritis vaccines
  • Track 28-9Yellow fever vaccines
  • Track 28-10Japanese encephalitis vaccines
  • Track 28-11Dengue fever vaccines
  • Track 28-12Typhoid fever vaccines
  • Track 28-13Pneumococcal vaccines
  • Track 28-14Tuberculosis vaccines
  • Track 28-15Measles vaccines
  • Track 28-16Rubella vaccines
  • Track 28-17Cholera vaccines
  • Track 28-18Meningococcal vaccines
  • Track 28-19Influenza vaccines
  • Track 28-20Diphtheria vaccines
  • Track 28-21Mumps vaccines
  • Track 28-22Tetanus vaccines
  • Track 28-23Hepatitis vaccines
  • Track 28-24Pertussis vaccines
  • Track 28-25Vaccines for emerging & re-emerging diseases
  • Track 29-1Children, Health Care Workers, Pregnancy
  • Track 29-2Tuberculin Skin Test (TST)
  • Track 29-3TB Blood Tests
  • Track 30-1 immunogenicity of stem cells
  • Track 30-2strategies to inhibit immune rejection to allograft stem cells
  • Track 30-3immune responses to cancer stem cells
  • Track 30-4mesenchymal stem cells in immune regulation
  • Track 31-1Ebola virus
  • Track 31-2Epidemiology and disease pathogenesis
  • Track 31-3Immune correlation of protection
  • Track 31-4Vaccine development
  • Track 32-1HIV variability
  • Track 32-2Lack of an ideal animal model
  • Track 32-3Natural immunity fails to clear HIV
  • Track 32-4HIV is a retrovirus- integrates into the host genome- short window of opportunity to control
  • Track 32-5Sexual transmission- need to block infection at mucosal surfaces
  • Track 32-6HIV targets cells of the immune system
  • Track 32-7HIV Env evasion mechanisms for induction of broadly neutralizing antibodies
  • Track 33-1Innate immunity & Diabetes
  • Track 33-2Central nervous system-targeted & Tissue-specific autoimmunity
  • Track 33-3Vaccines for Autoimmune skin disorders & Neuropathies
  • Track 34-1 Business Development & investment in New Approaches
  • Track 34-2Vaccines Investments & Partnerships
  • Track 34-3Vaccines Marketing & Cost effective production
  • Track 34-4Economic implications of bacterial resistance
  • Track 35-1Flu (influenza)
  • Track 35-2Tetanus toxoid